New research indicates that patients who discontinue popular slimming jabs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional diet and exercise plans.
Findings released in a prominent medical journal points out that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such medications should be cognizant of the risk of rapid weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting mass in about a year and a half.
Comparing Therapies
The research, which reviewed dozens of trials involving thousands of patients, contrasted the effects of these new drugs with older methods.
Scientists emphasize that people who lose weight through diet and exercise typically experience a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts suggest the mechanism of the jabs accounts for the amplified rebound.
The injections mimic a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement leads to hunger is uncontrolled, making excessive eating far more likely."
A Lifelong Disease?
Medical guidelines advise the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, considering the significant potential of weight regain, the therapy is often ongoing.
This opinion is supported by drug manufacturers, who note that the findings "highlight the chronic character of obesity," similar to managing conditions like diabetes.
User Experiences
Users who have come off the medication report a intense return of cravings.
"It felt as if a switch that goes on and you're instantly ravenous," described a patient.
This difficulty is worsened if individuals have not adopted lasting dietary or behavioural modifications during treatment.
Growing Adoption
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is higher among females compared to males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone cure and lasting health benefits relies on ongoing behavioural management.
